in patients with WHO functional II, III or IV symptoms’ Prostacyclin analogs epoprostenol Intravenous long-term treatment, via No ‘the infusion continuous intravenous infusion, in New York Heart Association functional class III or class IV patients with: Idiopathic pulmonary arterial hypertension Familial pulmonary arterial hypertension Pulmonary arterial hypertension associated with the scleroderma spectrum of diseases’ Iloprost Inhalational of patients with primary No ‘Treatment pulmonary hypertension or secondary Administered 6 pulmonary hypertension due to to 9 times per connective tissue disease or in moderate or severe stages of the disease. In addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.’ Treprostinil Continuous for the treatment of pulmonary 16 years ‘ ≥ subcutaneous arterial hypertension in patients with old infusion NYHA III-IV to diminish symptoms associated with exercise’ PDE-5 inhibitors Sildenafil Per oral and Per oral formulation: No intravenous treatment of patients with ‘the formulations pulmonary arterial hypertension Per oral: 20mg classified as WHO functional classes II (1 tablet) three and III, to improve exercise capacity. times a day Efficacy has been in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.’
in patients with WHO functional II, III or IV symptoms’ Prostacyclin analogs epoprostenol Intravenous infusion ‘the long-term treatment, via continuous intravenous infusion, in New York Heart Association functional class III or class IV patients with: Idiopathic pulmonary arterial hypertension Familial pulmonary arterial hypertension Pulmonary arterial hypertension associated with the scleroderma spectrum of diseases’ No Iloprost Inhalational Administered 6 to 9 times per ‘Treatment of patients with primary pulmonary hypertension or secondary pulmonary hypertension due to connective tissue disease or in moderate or severe stages of the disease. In addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.’ No Treprostinil Continuous subcutaneous infusion ‘ for the treatment of pulmonary arterial hypertension in patients with NYHA III-IV to diminish symptoms associated with exercise’ ≥ 16 years old PDE-5 inhibitors Sildenafil Per oral and intravenous formulations Per oral: 20mg (1 tablet) three times a day Per oral formulation: ‘the treatment of patients with pulmonary arterial hypertension classified as WHO functional classes II and III, to improve exercise capacity. Efficacy has been in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.’ No